Unicycive Therapeutics, Inc. (UNCY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 6.85 |
| Open | 6.97 |
| Day High | 8.24 |
| Day Low | 6.97 |
| 52-Week High | 8.74 |
| 52-Week Low | 3.71 |
| Volume | 2.67M |
| Average Volume | 720,756 |
| Market Cap | 169.14M |
| PE | -3.5 |
| EPS | -2.25 |
| Moving Average 50 Days | 7.47 |
| Moving Average 200 Days | 6.16 |
| Change | 1.02 |
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 04, 2026 12:05 PM GMT
LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire Inc.
Jan 29, 2026 2:15 PM GMT
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unic
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire Inc.
Jan 29, 2026 12:05 PM GMT
DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicy